(Reuters) – The U.S. Food and Drug Administration’s staff reviewers said on Tuesday safety data appeared generally favorable for administration of Pfizer Inc’s experimental respiratory syncytial virus (RSV) vaccine in pregnant women to protect their newborns.
The comments by the staff reviewers come ahead of meeting on Thursday of the FDA’s outside advisers, who provide non-binding recommendations to the health regulator.
(Reporting by Raghav Mahobe and Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)
